Goldman Sachs’s Burning Rock Biotech BNR Stock Holding History

Goldman Sachs’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,545	Closed	-$125K	–	5927
2022 Q4	$125K	Buy	+5,545	New	+$126K	﹤0.01%	5429
2022 Q1	–	Sell	-4,066	Closed	-$387K	–	6581
2021 Q4	$387K	Sell	4,066 -4,103	-50%	-$562K	﹤0.01%	5531
2021 Q3	$1.46M	Buy	8,169 +651	+9%	+$145K	﹤0.01%	4457
2021 Q2	$2.21M	Sell	7,518 -60,996	-89%	-$18M	﹤0.01%	4108
2021 Q1	$18.4M	Buy	+68,514	New	+$20.9M	﹤0.01%	2006
2020 Q4	–	Sell	-3,394	Closed	-$851K	–	5489
2020 Q3	$851K	Buy	3,394 +394	+13%	+$93.4K	﹤0.01%	4182
2020 Q2	$810K	Buy	+3,000	New	+$822K	﹤0.01%	4101

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's BNR Position: Q1 2023 in Review

Goldman Sachs sold out of Burning Rock Biotech (BNR) in Q1 2023, closing a stake of 5,545 shares — an estimated $125K sold.

Goldman Sachs first reported a position in BNR in Q2 2020 and held it in 7 quarters. The position peaked at $18.4M in Q1 2021. 34 funds tracked by Wall St. Rank hold BNR as of Q1 2023.

Goldman Sachs reported no remaining Burning Rock Biotech position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 5,545 Burning Rock Biotech shares in Q1 2023, an estimated $125K.
Goldman Sachs first reported a position in Burning Rock Biotech in Q2 2020 and held it in 7 quarters.
Goldman Sachs's Burning Rock Biotech position peaked at $18.4M in Q1 2021.
34 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.